Alerts will be sent to your verified email
Verify EmailLINCOLN
|
Lincoln Pharma
|
Venus Remedies
|
Kwality Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
8.98 % | n/a | n/a |
|
R&D as a % of Total Sales
|
1.88 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
15.1 % | 8.87 % | 25.27 % |
|
5yr average Equity Multiplier
|
1.26 | 1.32 | 1.96 |
|
5yr Average Asset Turnover Ratio
|
0.82 | 0.96 | 1.05 |
|
5yr Avg Net Profit Margin
|
14.59 % | 6.91 % | 11.66 % |
|
Price to Book
|
1.37 | 1.68 | 3.22 |
|
P/E
|
12.24 | 14.24 | 19.02 |
|
5yr Avg Cash Conversion Cycle
|
-6.41 Days | 46.96 Days | 55.02 Days |
|
Inventory Days
|
43.91 Days | 75.64 Days | 67.04 Days |
|
Days Receivable
|
91.75 Days | 54.28 Days | 132.46 Days |
|
Days Payable
|
128.38 Days | 58.86 Days | 126.93 Days |
|
5yr Average Interest Coverage Ratio
|
63.13 | 396.11 | 16.13 |
|
5yr Avg ROCE
|
19.81 % | 8.42 % | 34.73 % |
|
5yr Avg Operating Profit Margin
|
18.35 % | 10.14 % | 23.23 % |
|
5 yr average Debt to Equity
|
0.0 | 0.08 | 0.46 |
|
5yr CAGR Net Profit
|
5.76 % | -6.01 % | 21.34 % |
|
5yr Average Return on Assets
|
11.92 % | 6.69 % | 12.96 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
49.78 % | 41.76 % | 54.83 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
5.7 % | 0.0 | 0.38 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Lincoln Pharma
|
Venus Remedies
|
Kwality Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|